Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate if high-dose (80mg/day) atorvastatin might exert an adjunctive anti-platelet effect compared to high-dose clopidogrel (150mg/day) in stable patients with high on-treatment reactivity according to a point-of-care platelet function assay.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ospedale Misericordia e Dolce
• Treatments: Atorvastatin; Atorvastatin Calcium; Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• Stable angina

• candidates to drug eluting stent implantation

• High on-treatment platelet reactivity according to a point-of-care platelet function test

Exclusion Criteria:

• chronic therapy with statins

• inability to provide informed consent

• intolerance to statins

• acute or chronic liver failure or ALT > 2 times ULN

• known myopathy

• CKD stage IV or dialysis treatment

• pregnancy or breast-feeding

• malignancy